Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-39091

ABSTRACT: Expression data of A375 melanoma cells after DMSO or MLN4924 +/- Nutlin treatment for 26 hours

PROVIDER: E-GEOD-39091 | ExpressionAtlas | 2025-01-24

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-39091-analysis-methods.tsv	Tabular
	E-GEOD-39091-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-39091-configuration.xml	Xml
	E-GEOD-39091-percentile-ranks.tsv	Tabular
	E-GEOD-39091.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 174

Similar Datasets

Homo sapiens

Project description:Expression data of A375 melanoma cells after DMSO or MLN4924 +/- Nutlin treatment for 26 hours

| PRJNA169929 | ENA

Gene expression in Vemurafenib-treated A375 and A2058 melanoma cell lines

Project description:Human melanoma cell line A375 and A2058 were incubated with DMSO (control group) or Vemurafenib (1 μM in DMSO) for 72 hours. Total RNA was isolated with Qiagen RNA isolation kit; 1.5 μg of total RNA was used as template for cDNA synthesis.

2015-12-02 | GSE52882 | GEO

Synergy from Gene Expression and Network Mining (SynGeNet) method predicts genotype-specific synergistic drug combinations in melanoma

Project description:Using our computational method SynGeNet to evaluate genomic and transcriptomic data characterizing four major genomic subtypes of melanoma, we selected the top ranked drug combination for BRAF-mutation melanoma for subsequent validaiton. Here we present drug-induced gene expression data from the BRAF-mutant A375 melanoma cell line in response to four treatment conditions: vehicle control (DMSO), vemurafenib alone, tretinoin (ATRA) alone and vemurafenib+tretinoin combination.

2018-07-01 | GSE109731 | GEO

Human A375 melanoma cell line treated with ciclopirox and crizotinib

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59340 | GEO

Human A375 melanoma cell line treated with trifluorothymidine (TFT) and lactimidomycin (LTM)

Project description:To generate drug signatures in human A375 melanoma cell lines. A375 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59183 | GEO

Homo sapiens

Project description:Expression data of A375 melanoma cells after DMSO or MLN4924 treatment from 1 hour to 24 hour

| PRJNA143311 | ENA

Cancer genes disfavoring T cell immunity identified via integrated systems approach

Project description:A375 melanoma cells were transduced with Cas9 and non-targeting (NT) or BIRC2-targeting sgRNAs. Cells were cultured for 20 days post gene-editing and cell pellets were collected for analysis. Separately, A375 melanoma cells were treated with LCL161 for 16 hours and cell pellets were collected for analysis.

2022-06-27 | MSV000089737 | MassIVE

Expression data from A375 melanoma parental and persister cells

Project description:Identify transcriptionnally and translationally regulated mRNA in melanoma parental and persister cells In this dataset, we include expression data of A375 melanoma drug-naïve parental cells and A375 melanoma persister cells that survived from BRAF and MEK inhibition. The expression data are studied in both total RNA and polysome-bounded RNA.

2019-09-20 | GSE137724 | GEO

shRNA profiling of melanoma A375 cells stably expressing a shRNA construct for doxycycline-inducible knockdown of B-Raf (2 mg/ml Dox, antitumor efficacy of RAF inhibitor GDC-0879 involving BRAFV600E mutational status and ERK/MAPK pathway suppression

Project description:Unsupervised hierarchical clustering revealed a strong similarity in gene modulation resulting from either compound treatment or BRAF ablation mediated by RNA interference relative to DMSO-treated control samples . Experiment Overall Design: We have generated melanoma A375 cells stably expressing a shRNA construct for doxycycline-inducible knockdown of B-Raf (2 mg/ml Dox, 48h). Small molecule treatment was at 1000nM R341787, 24h.

2009-10-10 | E-GEOD-13487 | biostudies-arrayexpress

E-GEOD-30531

Project description:Expression data of A375 melanoma cells after DMSO or MLN4924 treatment from 1 hour to 24 hour

2025-01-24 | E-GEOD-30531 | ExpressionAtlas